TIDMNSCI
NetScientific PLC
23 February 2021
NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS COVID-19 Vaccine Commercialisation Update
Blanver joins PDS-Farmacore COVID-19 Vaccine Consortium
PDS Biotech and Farmacore Announce Blanver to Join Consortium to
Commercialize Novel Versamune(R) -Based T-Cell Inducing COVID-19
Vaccine
London, UK - 23 February 2021 - NetScientific plc (AIM: NSCI),
the life sciences and sustainability technology investment and
commercialisation Group, announces that Blanver Farmoquímica e
Farmacêutica S.A. ("Blanver") has joined the COVID-19 vaccine
commercialisation consortium jointly run by the Group's portfolio
company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) and
Farmacore Biotechnology.
Under the terms of the agreement, São Paulo-based Blanver will
manufacture, promote, distribute, and commercialize the
Versamune(R) -based COVID-19 vaccine in Latin America. As the
licence holder of Versamune-CoV2-FC (PDS0203) in Latin America,
Farmacore will continue to lead the regulatory and clinical trial
efforts in Brazil and has selected a top clinical research
organization to conduct clinical trials in Brazil. PDS Biotech will
continue to contribute scientific expertise and operational
support.
NetScientific holds 5.75% of PDS on an undiluted basis.
Dr. Ilian Iliev, CEO of NetScientific and Director of PDS
Biotechnology commented: "We are pleased with PDS' continued
progress in its pipeline of infectious disease vaccines and cancer
immunotherapies."
NetScientific holds approximately 5.75% of PDS' undiluted share
capital.
The full text of the announcement from PDS Biotechnology are set
up below and can be found here:
https://pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/485-iotechandarmacorennouncelanvertooinonsorti20210222
# # #
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company's proprietary
Versamune(R) T-cell activating technology, and Farmacore
Biotechnology today announced that Blanver Farmoquímica e
Farmacêutica S.A. has joined their consortium to develop and
commercialize a novel COVID-19 vaccine in Latin America.
Blanver is a leading Brazilian Pharmaceutical Company focused on
the development, manufacture, and commercialization of innovative
pharmaceutical products. Under the terms of the agreement, São
Paulo-based Blanver will manufacture, promote, distribute, and
commercialize the Versamune(R) -based COVID-19 vaccine in Latin
America. As the license holder of Versamune-CoV2-FC (PDS0203) in
Latin America, Farmacore will continue to lead the regulatory and
clinical trial efforts in Brazil and has selected a top clinical
research organization to conduct clinical trials in Brazil. PDS
Biotech will continue to contribute scientific expertise and
operational support.
"Innovation is part of Blanver's DNA," commented Sergio
Frangioni, Blanver Group CEO. "We are honored to join the
consortium with PDS Biotech and Farmacore as our partners in Latin
America to advance this innovative treatment to patients quickly in
the fight against this deadly disease."
"We are delighted to have these two expert partners in Latin
America, who provide a combination of scientific and manufacturing
expertise in addition to local market experience to help broaden
the potential reach of a Versamune(R) -based COVID-19 vaccine to
patients," said Dr. Frank Bedu-Addo, CEO of PDS Biotech.
"We are excited to add Blanver's wealth of experience in
development and commercialization across Latin America to this
consortium as we continue in the fight against this global
pandemic," said Helena Faccioli, CEO of Farmacore.
The consortium is in active discussions with specific agencies
of the Brazilian government to extend the preclinical funding to
cover the upcoming human clinical trials anticipated to begin
during the first half of 2021.
The novel vaccine combines PDS Biotech's Versamune(R) T-cell
activating technology with a SARS-CoV-2 recombinant protein antigen
co-developed with Farmacore. As previously disclosed, preclinical
data demonstrated that the vaccine elicits a 30-45 fold increase in
the induction of highly active and potent virus-specific T-cells
within 14 days of treatment compared to the antigen without
Versamune(R) . The study also demonstrated induction of
long-lasting virus-specific memory T-cells necessary for longer
term protection. The studies also demonstrated strong, long-lasting
induction of neutralizing antibodies. Notably, the vaccine contains
a protein derived from the spike (S) protein that also includes the
receptor binding domain (RBD) as well as other potentially
non-mutating regions of the virus that can be recognized and
attacked by T-cells. The vaccine is based on recombinant proteins
(subunit vaccine) and does not require the use of attenuated
viruses, traditional adjuvants, DNA or RNA to induce robust
protective immune responses. In addition, a recent Phase I study of
PDS0101, a Versamune(R) -based HPV16 subunit vaccine, demonstrated
powerful T-cell responses and an attractive human safety profile
with no serious or dose-limiting toxicities, presenting strong
potential for an attractive safety profile for the novel
Versamune(R) -based SARS-CoV-2 vaccine.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a
growing pipeline of cancer immunotherapies and infectious disease
vaccines based on the Company's proprietary Versamune(R) T-cell
activating technology platform. Versamune(R) effectively delivers
disease-specific antigens for in vivo uptake and processing, while
also activating the critical type 1 interferon immunological
pathway, resulting in production of potent disease-specific killer
T-cells as well as neutralizing antibodies. PDS Biotech has
engineered multiple therapies, based on combinations of
Versamune(R) and disease-specific antigens, designed to train the
immune system to better recognize disease cells and effectively
attack and destroy them. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
About Farmacore Biotechnology
Farmacore Biotechnology is a biotechnology company, founded in
2005 as a startup, focusing on R&D of innovative
immunobiological products for use in the human and veterinary
health sectors. It is a technology-based company that conducts
research and development of biotechnological products and processes
for the human and veterinary sectors. It develops innovative
biotechnological and immunobiological products and adds value to
them in all stages of development, from project design to
biomolecule production www.farmacore.com.br .
About Blanver Farmoquímica
Blanver Farmoquímica e Farmacêutica S.A. is a Brazilian company,
founded in 1984, focused on R&D, manufacture and sale of
innovative medicines and active pharmaceutical ingredients (APIs).
The company plays in the segments of HIV, Hepatitis, Oncology and
Hematology, providing high quality products for expanding the
population's access to medicines through partnerships with the
Ministry of Health and official laboratories. Blanver is committed
in always looking for innovations that will improve people's health
and quality of life.
About Versamune-CoV-2FC/PDS0203
PDS0203 is an investigational vaccine designed for the
prevention of COVID-19 being developed for Latin America by a
consortium that includes PDS Biotech, Farmacore Biotechnology and
Blanver Farmoquímica. The vaccine combines the utility of PDS
Biotech's Versamune(R) platform with a recombinant native Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein
recognizable by our immune system (antigen). The Versamune(R)
platform, due to its unique ability to induce both antibody and
polyfunctional CD8+ killer and CD4+ helper T-cell responses is
being utilized to develop a next generation vaccine that may more
effectively prevent COVID-19.
Forward Looking Statements
This communication contains forward-looking statements
(including within the meaning of Section 21E of the United States
Securities Exchange Act of 1934, as amended, and Section 27A of the
United States Securities Act of 1933, as amended) concerning PDS
Biotechnology Corporation (the "Company") and other matters. These
statements may discuss goals, intentions and expectations as to
future plans, trends, events, results of operations or financial
condition, or otherwise, based on current beliefs of the Company's
management, as well as assumptions made by, and information
currently available to, management. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as "may," "will," "should," "would," "expect,"
"anticipate," "plan," "likely," "believe," "estimate," "project,"
"intend," "forecast." "guidance", "outlook" and other similar
expressions among others. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: the Company's ability to protect its
intellectual property rights; the Company's anticipated capital
requirements, including the Company's anticipated cash runway and
the Company's current expectations regarding its plans for future
equity financings; the Company's dependence on additional financing
to fund its operations and complete the development and
commercialization of its product candidates, and the risks that
raising such additional capital may restrict the Company's
operations or require the Company to relinquish rights to the
Company's technologies or product candidates; the Company's limited
operating history in the Company's current line of business, which
makes it
difficult to evaluate the Company's prospects, the Company's
business plan or the likelihood of the Company's successful
implementation of such business plan; the timing for the Company or
its partners to initiate the planned clinical trials for its lead
asset PDS0101; the future success of such trials; the successful
implementation of the Company's research and development programs
and collaborations, including any collaboration studies concerning
PDS0101 and the Company's interpretation of the results and
findings of such programs and collaborations and whether such
results are sufficient to support the future success of the
Company's product candidates; the acceptance by the market of the
Company's product candidates, if approved; the timing of and the
Company's ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, the Company's product candidates; and other
factors, including legislative, regulatory, political and economic
developments not within the Company's control, including unforeseen
circumstances or other disruptions to normal business operations
arising from or related to COVID-19. The foregoing review of
important factors that could cause actual events to differ from
expectations should not be construed as exhaustive and should be
read in conjunction with statements that are included herein and
elsewhere, including the risk factors included in the Company's
annual and periodic reports filed with the SEC. The forward-looking
statements are made only as of the date of this press release and,
except as required by applicable law, the Company undertakes no
obligation to revise or update any forward-looking statement, or to
make any other forward-looking statements, whether as a result of
new information, future events or otherwise.
# # #
For more information, please contact:
NetScientific Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser
and Broker)
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
Walbrook PR
Anna Dunphy/ Nick Rome/ Paul McManus/ 07876 741 001 or 07748 325 236
Nicholas Johnson or 07980 541 893
or 07884 664 686
About NetScientific
NetScientific Plc is a life sciences and sustainability
technology investment and commercialisation Group, leveraging
trans-Atlantic relationships and global opportunities to deliver
shareholder value.
For more information, please visit the website at
www.NetScientific.net
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABRGDDGUDDGBD
(END) Dow Jones Newswires
February 23, 2021 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024